SOLASIA-PHARMA
15.6.2020 09:50:08 CEST | Business Wire | Press release
Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced the positive results from the pivotal Phase 2 study with SP-02 (a new anti-cancer drug, international generic name: darinaparsin, hereinafter “darinaparsin”) for relapsed or refractory peripheral T-cell lymphoma (hereinafter “PTCL”) in Asia.
- The primary endpoint (antitumor effect) was achieved.
- No new safety concerns were identified in the safety analysis.
- This study was conducted as the final registration trial for the indication of relapsed or refractory PTCL. Solasia begins preparing for the NDA Filing.
Darinaparsin is a novel mitochondrial targeting drug (organic arsenic compound) that has been developed for the treatment of various hematological cancers and solid cancers. This study was conducted as a multinational, multicentre, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of darinaparsin monotherapy in relapsed or refractory patients with PTCL in Japan, South Korea, Taiwan and Hong Kong.
Solasia holds an exclusive worldwide license to develop and commercialize darinaparsin. For Japan market, Solasia has already entered into an exclusive license agreement with Meiji Seika Pharma Co., Ltd., for the commercialization of darinaparsin, and for Latin America, with HB Human BioScience SAS. Based on these positive results, Solasia will actively seek licensing partners for the United States, Europe and other regions.
About darinaparsin (SP-02)
Darinaparsin is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers. In a US Phase 2 study, darinaparsin demonstrated evidence of clinical activity in lymphoma, in particular PTCL. Furthermore, the Phase 1 study done in US, and the Pan-Asian Phase 1 study both demonstrated positive efficacy and safety. Darinaparsin has been granted orphan drug designation in US and EU.
For more information, please see at https://www.solasia.co.jp/en/pipeline/sp-02.html
About peripheral T-cell lymphoma (PTCL)
Malignant lymphoma is a general term to describe tumors that have developed from lymphocytes, mainly in the immune tissue (lymph nodes). A variety of clinical pathological characterizations present in malignant lymphoma. Malignant lymphoma is classified as Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL). NHL mainly consists of B-cell lymphoma and T-cell lymphoma. It is reported that relatively higher incidence of T-cell lymphoma rather than B-cell lymphoma in Japan and Asia. PTCL is a major subtype of T-cell lymphoma with a high incidence rate. Although there is no standard treatment established to treat PTCL, CHOP therapy is widely used as front line treatment. However, there is a large need for more effective and safer therapies as the clinical efficacy of CHOP to treat PTCL is limited. In addition, there are no standard salvage therapies for PTCL, and new, breakthrough therapies are needed.
About Solasia
Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers.
For more information, please visit https://www.solasia.co.jp/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005228/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 02:00:00 CEST | Press release
Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 01:58:00 CEST | Press release
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform
Andersen Global styrker sine kompetencer inden for skat og global mobilitet i Tyskland2.7.2026 00:13:00 CEST | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse gennem en samarbejdsaftale med Lohr and Company (L+C), der er en erfaren skatterådgivningsvirksomhed, der leverer praktiske og fleksible løsninger inden for skattecompliance, internationale skatteforhold, global mobilitet og transfer pricing. L+C har hovedkontor i Tyskland og er også til stede i Østrig og rådgiver store multinationale selskaber, familieejede virksomheder, familievirksomheder, fonde og formuende privatpersoner. L+C blev grundlagt i 2001 og har specialiseret sig i global mobilitet, opkøb og fusioner, international skattelovgivning, rapportering mellem lande og transfer pricing, herunder rapportering i henhold til Pillar 2. Derudover bistår L+C sine kunder med trusts og fonde, skattecompliance, løn- og regnskabsadministration samt privatøkonomisk rådgivning. "Samarbejdet med Andersen Global er et vigtigt skridt i udvidelsen af vores internationale kompetencer og styrker den værdi, vi skaber for kunder, der navigerer i stadig mer
Robinhood Chooses Morpho to Power New Earn Product1.7.2026 21:15:00 CEST | Press release
Morpho now powers the infrastructure behind some of the most widely used retail financial platforms in the United States, bringing more options for onchain yield to millions of customers through the apps they already use. Morpho, the open blockchain-based credit network, today announced it will power Robinhood’s new Earn product, enabling Robinhood's millions of eligible users more options to earn yield onchain via a self-custody wallet, directly within the Robinhood app. The product will roll out progressively to Robinhood's US customer base over the coming weeks. The Robinhood Earn product aims to provide risk-adjusted yield on idle balances using USDG, a dollar-pegged stablecoin. Morpho serves as the underlying credit network, Steakhouse Financial curates the vault infrastructure supporting the product, and Robinhood Chain acts as the settlement layer. The product is delivered through a seamless experience in the Robinhood app. Morpho operates as an open network on the blockchain. L
Photonics Innovators Worldwide Invited to Compete for SPIE Prism Awards1.7.2026 20:33:00 CEST | Press release
19th annual award honors exceptional new products transforming light-based technologies SPIE, the international society of optics and photonics, invites the optics and photonics community to apply for this year’s SPIE Prism Awards, which recognize outstanding new products making waves on the market. Honorees will be announced at the highly-anticipated award ceremony on 3 February 2027 at SPIE Photonics West in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701642411/en/ SPIE Prism Awards honor exceptional new products transforming optics and photonics technologies. These awards, dubbed the “Oscars of Photonics,” provide scientists and engineers in the optics and photonics industry the opportunity to showcase their contributions to the field. Finalists and winners receive extensive print, web, and onsite promotion at SPIE Photonics West, which draws more than 22,000 researchers and industry leade
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom